[1]
|
Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis
Frontiers in Endocrinology,
2022
DOI:10.3389/fendo.2022.818537
|
|
|
[2]
|
Effect of dipeptidyl peptidase‐4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A meta‐analysis of randomised controlled trials
International Journal of Clinical Practice,
2021
DOI:10.1111/ijcp.14213
|
|
|
[3]
|
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
Journal of Diabetes Research,
2018
DOI:10.1155/2018/1232583
|
|
|
[4]
|
Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
Journal of Diabetes Investigation,
2017
DOI:10.1111/jdi.12587
|
|
|
[5]
|
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes
Cardiovascular Diabetology,
2017
DOI:10.1186/s12933-016-0493-3
|
|
|
[6]
|
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Cardiovascular Diabetology,
2017
DOI:10.1186/s12933-017-0564-0
|
|
|
[7]
|
Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
Journal of Diabetes Investigation,
2017
DOI:10.1111/jdi.12587
|
|
|
[8]
|
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
Cardiovascular Diabetology,
2017
DOI:10.1186/s12933-017-0607-6
|
|
|
[9]
|
Vascular Protection with Dipeptidyl Peptidase-IV inhibitors in Diabetes: Experimental and Clinical Therapeutics
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
2015
DOI:10.1002/phar.1547
|
|
|
[10]
|
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
Scientific Reports,
2015
DOI:10.1038/srep10202
|
|
|
[11]
|
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
Scientific Reports,
2015
DOI:10.1038/srep10202
|
|
|
[12]
|
Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report
Cardiovascular Diabetology,
2013
DOI:10.1186/1475-2840-12-8
|
|
|